Literature DB >> 28561235

How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS).

Thomas O Bergmeijer1,2, Thea C Godschalk1,2, Paul W A Janssen1,2, Kim van den Berge1,2, Nicoline J Breet1,2, Johannes C Kelder1,2, Christian M Hackeng2,3, Jurriën M Ten Berg1,2.   

Abstract

Antiplatelet therapy plays a pivotal role in patients with an ST-segment elevation myocardial infarction (STEMI) to prevent further atherothrombotic events, such as stent thrombosis. Although the risk of stent thrombosis is highest in the first hours after primary percutaneous coronary intervention (pPCI), little is known about when an adequate level of platelet inhibition is achieved following a clopidogrel or ticagrelor loading dose in STEMI patients. Patients presenting with STEMI in whom pPCI was performed and who were loaded with 600 mg clopidogrel or 180 mg ticagrelor were eligible for enrolment in this nonrandomized, open label, single-center study. Platelet reactivity was measured before PCI, 6 and 24 hours after loading dose and after 2, 7, and 14 days, using the VerifyNow P2Y12 assay as well as 20 µmol/L adenosine diphosphate stimulated light transmittance aggregometry (LTA). We analyzed the time until a VerifyNow result of < 236 P2Y12 reaction units or LTA maximum platelet aggregation of < 64.5% was reached. A total of 28 patients were participated in this study. Platelet reactivity dropped below the high platelet reactivity cutoff level after 11.4 (VerifyNow) and 5.7 (LTA) hours in patients who were loaded with clopidogrel, and after 2.4 (VerifyNow) and 3.9 (LTA) hours in patients who were loaded with ticagrelor. Despite the administration of a clopidogrel or ticagrelor loading dose, it still takes multiple hours (2-11) to reach adequate platelet inhibition in STEMI patients. This might indicate the need for additional antiplatelet therapy in the first hours after loading in patients undergoing pPCI with stenting. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28561235     DOI: 10.1055/s-0037-1599156

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  5 in total

1.  Platelet inhibition to target reperfusion injury trial: Rationale and study design.

Authors:  Heerajnarain Bulluck; Mervyn H H Chan; Jennifer A Bryant; Ping Chai; Ashish Chawla; Terrance S Chua; Yiu-Cho Chung; Gao Fei; Hee H Ho; Andrew F W Ho; Andrew J Hoe; Syed S Imran; Chi-Hang Lee; Swee H Lim; Boon W Liew; Patrick L Z Yun; Marcus O E Hock; Valeria Paradies; Matthew T Roe; Lynette Teo; Aaron S Wong; Evelyn Wong; Philip E Wong; Timothy Watson; Mark Y Chan; Jack W Tan; Derek J Hausenloy
Journal:  Clin Cardiol       Date:  2018-12-17       Impact factor: 2.882

2.  Translation of experimental cardioprotective capability of P2Y12 inhibitors into clinical outcome in patients with ST-elevation myocardial infarction.

Authors:  Marie V Hjortbak; Kevin K W Olesen; Jacob M Seefeldt; Thomas R Lassen; Rebekka V Jensen; Alexander Perkins; Matthew Dodd; Tim Clayton; Derek Yellon; Derek J Hausenloy; Hans Erik Bøtker
Journal:  Basic Res Cardiol       Date:  2021-05-26       Impact factor: 17.165

3.  Functional Outcome and Safety of Intracranial Thrombectomy After Emergent Extracranial Stenting in Acute Ischemic Stroke Due to Tandem Occlusions.

Authors:  Philipp Bücke; Marta Aguilar Pérez; Muhammad AlMatter; Victoria Hellstern; Hansjörg Bäzner; Hans Henkes
Journal:  Front Neurol       Date:  2018-11-20       Impact factor: 4.003

4.  Will intravenous paracetamol crush fentanyl in patients undergoing PCI for STEMI?

Authors:  J M Ten Berg; D M F Claassens
Journal:  Neth Heart J       Date:  2019-04       Impact factor: 2.380

5.  Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI.

Authors:  Charles V Pollack; W Frank Peacock; Durgesh D Bhandary; Steven H Silber; Narinder Bhalla; Sunil V Rao; Deborah B Diercks; Alex Frost; Sripal Bangalore; John F Heitner; Charles Johnson; Renato DeRita; Naeem D Khan
Journal:  Crit Pathw Cardiol       Date:  2020-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.